# Lipoproteïne(a) en cardiovasculaire ziekte: van genetische risicofactor naar therapeutisch doelwit

*geplaatst 2026-02-07 · Cholesterol · Cells · doi 10.3390/cells15040315 · https://hartvaat.nl/2026/02/07/lipoproteine-a-en-cardiovasculaire-ziekte-van-genetische-risicofactor-naar-thera/*

Een uitgebreide review over de staat van Lp(a) als cardiovasculaire risicofactor. Verhoogd Lp(a) treft circa 20% van de wereldbevolking en is causaal gelinkt aan atherosclerose en aortaklepstenose. Nieuwe therapieën zoals pelacarsen, olpasiran en lepodisiran bevinden zich in fase III-trials en bieden voor het eerst perspectief op gerichte Lp(a)-verlaging.

## English: Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.

A comprehensive review of lipoprotein(a) as a cardiovascular risk factor, covering its causal link to atherosclerosis and aortic valve stenosis, and emerging phase III therapies including pelacarsen, olpasiran, and lepodisiran.

## Abstract (original, from the publication)

Lipoprotein(a) [Lp(a)] is a causal, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Although elevated Lp(a) affects approximately 20% of the global population, specific pharmacological options have long been unavailable, leaving a major gap in residual risk management. This review synthesizes current understanding of Lp(a) molecular architecture, genetics, and metabolism, and integrates mechanistic evidence linking Lp(a) to pro-atherogenic, pro-inflammatory, and pro-thrombotic pathways. We summarize epidemiological and genetic data associating Lp(a) with a broad spectrum of cardiovascular outcomes and discuss current clinical guidelines on screening and risk stratification. Furthermore, we provide an up-to-date overview of the emerging therapeutic landscape, including RNA-targeted therapies and novel oral small molecules. With pivotal phase 3 outcome trials nearing completion, the field is transitioning from viewing Lp(a) as an untreatable biomarker to an actionable therapeutic target, with important implications for precision cardiovascular prevention.

Auteurs: Hyeong Rok Yun, Manish Kumar Singh, Sunhee Han, Jyotsna S Ranbhise, Joohun Ha, Sung Soo Kim, Insug Kang

---
Bron: Cells, https://doi.org/10.3390/cells15040315. Bijgewerkt 2026-07-03T13:24:26Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.